

What is claimed is:

- 1) Use of MSC in the manufacture of a medicament for treating liver disease wherein MSC is to be administered to a patient in need thereof.
- 2) The use of claim 1 wherein said MSC comprise activated MSC.
- 3) The use of claim 2 wherein said activated MSC comprise MSC activated with at least one of interferon gamma (IFN γ), Tumor Necrosis Factor alpha (TNF α), and interleukin-17 (IL-17).
- 4) The use of claim 2 wherein said activated MSC comprise MSC activated with at least two of interferon gamma (IFN γ), Tumor Necrosis Factor alpha (TNF α), and interleukin-17 (IL-17).
- 5) The use of claim 2 wherein said activated MSC comprise MSC activated with interferon gamma (IFN γ), Tumor Necrosis Factor alpha (TNF α), and interleukin-17 (IL-17).
- 6) The use of claim 3 wherein said patient is a mammal.
- 7) The use of claim 4 wherein said mammal is a human.
- 8) The use of claim 1, wherein said administration comprises at least one of subcutaneous, intra-articular, intra-lesional, intravenous, intra-peritoneal or intramuscular administration
- 9) The use of claim 8, wherein said MSC are autologous.
- 10) The use of claim 8, wherein said MSC are allogenic.
- 11) The use of claim 9 or 10 wherein said MSC are to be administered in a dose between 1×10^3 cells and 1×10^{12} cells.
- 12) The use of claim 11, wherein said dose comprises at least two doses.
- 13) The use of claim 12, wherein said dose comprises at least three doses.
- 14) The use of claim 13, wherein said dose comprises at least four doses.

- 15) The use of claim 14, wherein said dose comprises at least five doses.
- 16) A method of activating a cytokine-producing MSC, comprising stimulating the MSC with at least one of interferon gamma (IFN γ), Tumor Necrosis Factor alpha (TNF α), and interleukin-17 (IL-17).
- 17) A method of activating a cytokine-producing MSC, comprising stimulating the MSC with at least two of interferon gamma (IFN γ), Tumor Necrosis Factor alpha (TNF α), and interleukin-17 (IL-17).
- 18) A method of activating a cytokine-producing MSC, comprising stimulating the MSC with interferon gamma (IFN γ), Tumor Necrosis Factor alpha (TNF α), and interleukin-17 (IL-17).
- 19) The method of any of claims 16-18, wherein said cytokine comprises at least one of IL-6, IL-17A, IFN gamma, TNF α , TGF β , MCP1, HGF, IL-8, TIMP-1, TIMP-2, VEGF, IDO, MIP-1b, and IL-10.